Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START: Selinexor and Talazoparib in Advanced Solid Tumors and TNBC
NCT05035745Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Mar 2021
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in solid tumor, triple-negative breast cancer (TNBC), sponsored by National University Hospital. Started Mar 2021; status: recruiting.
02
Drugs
selinexor
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05035745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035745.